ADCs targeting tumor-specific antigens, such as Enfortumab vedotin (anti-Nectin-4) and Sacituzumab govitecan (anti-Trop-2), are being combined with platinum-based chemotherapies to enhance their cytotoxic effect (Belluomini et al., 2023a; Wong and Rosenberg, 2021). This evidence concerns the gene TACSTD2 and neoplasm.